ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

RVNC Revance Therapeutics Inc

2.8515
0.0115 (0.40%)
Pre Market
Last Updated: 08:11:49
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,467
Bid Price 2.88
Ask Price 2.94
News -
Day High

Low
2.59

52 Week Range

High
32.45

Day Low
Share Name Share Symbol Market Stock Type
Revance Therapeutics Inc RVNC NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.0115 0.40% 2.8515 08:11:49
Open Price Low Price High Price Close Price Previous Close
2.84
Trades Shares Traded Average Volume 52 Week Range
9 3,467 - 2.59 - 32.45
Last Trade Type Quantity Price Currency
08:11:49 formt 1,000 US$ 2.8515 USD

Revance Therapeutics (RVNC) Options Flow Summary

Overall Flow

Bearish

Net Premium

-18k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Revance Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
250.53M 88.21M - 234.04M -323.99M -3.67 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Revance Therapeutics News

Date Time Source News Article
5/28/202415:05Business WireRevance to Participate in Upcoming Investor Conferences
5/09/202415:33Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/09/202415:08Edgar (US Regulatory)Form 8-K - Current report
5/09/202415:06Business WireRevance Reports First Quarter 2024 Financial Results,..
5/09/202415:05Business WireRevance Expands into the U.S. Therapeutics Market with the..
5/02/202415:05Business WireRevance to Release First Quarter 2024 Financial Results on..
4/12/202407:00Business WireRevance to Present New DAXXIFY® Data at the American Academy..
3/27/202415:05Business WireRevance Reports Inducement Grants Under Nasdaq Listing Rule..
3/08/202415:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/05/202416:08Edgar (US Regulatory)Form 8-K - Current report
3/05/202416:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
3/04/202416:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RVNC Message Board. Create One! See More Posts on RVNC Message Board See More Message Board Posts

Historical RVNC Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.7453.002.592.801,955,0230.10653.88%
1 Month4.004.4752.593.232,400,282-1.15-28.71%
3 Months6.306.4682.593.931,945,298-3.45-54.74%
6 Months7.219.7452.595.251,819,840-4.36-60.45%
1 Year31.0632.452.5910.301,790,941-28.21-90.82%
3 Years28.5937.982.5917.391,283,470-25.74-90.03%
5 Years10.8537.982.5918.37988,193-8.00-73.72%

Revance Therapeutics Description

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products.

Your Recent History

Delayed Upgrade Clock